## Ocrelizumab (Ocrevus) Provider Order Form rev. 01/02/2024

Provider Name (print)

, ,							
PATIENT INFORMATION	Referral Status:	□ New R	eferral	☐ Updated O	rder 🗆	Order Renewal	
Patient Name: .		DOB: Patient Phone:					
Patient Address:			Patie	ent Email:			
Allergies:		□ NKDA	Weight	(lbs/kg):	Height	t (in/cm):	
Sex: □ M / □ F Date of Last Infusion:	Next Due Date	:	Prefe	rred Location:			
DIAGNOSIS (Please provide ICD-10 code in space	provided)						
Multiple Sclerosis: ☐ RRMS	□ PPMS		SPMS				
Other: Description:							
THERAPY ADMINISTRATION & DOSING  ☐ Induction: Administer Ocrevus 300 mg IV in 250 ml saline on Week 0 and Week 2 followed by 600mg IV in normal saline 6 months after initial dose  ☐ Maintenance: Administer Ocrevus 600 mg IV in 500 normal saline every 6 months  ☑ Observe patient for hypersensitivity reaction for a pminutes following each infusion.  ADDITIONAL ORDERS	0.9% normal [6] 500 ml 0.9% [6] 0 ml 0.9% [6] 0 eriod of 60 [6] 1 [6] 1 [7] 1 [8] 2 [8] 3 [8] 4 [8] 6 [8] 6 [8] 6 [8] 6 [8] 6 [8] 7 [8] 7 [8] 8 [8] 8 [8] 8 [8]	9% ☐ Loratadine 10mg PO ☐ Pepcid 20mg ☐ PO / ☐ IVP ☑ Benadryl ☐ 25mg / ☐ 50mg ☐ PO / ☐ IVP ☑ Solumedrol 125mg IVP				d/recent surgery. en every 30 t experienced a vus infusion may nce quick notes fo	
PROVIDER INFORMATION							
Preferred Contact Name: Ordering Provider:	Preferred Contact Email: Provider NPI:						
Referring Practice Name:	Pho	ne:	viuei INPI:	Fax:			
Practice Address:	City		St	ate:	Zip (	Code:	
DECLUDED DOCUMENTATION OFFICIALIST	·				•		
REQUIRED DOCUMENTATION CHECKLIST (A Required Documentation: Patient demos, copy of f treatment failures or contraindications, MRI results Required Labs: Negative Hepatitis B	ront and back of pr						

Date

**Provider Signature**